In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ring Therapeutics Turns To Anelloviruses To Disrupt Gene Therapy Space

Executive Summary

Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.

You may also be interested in...



Robotics Player CMR Has Critical MAS In Its Sights

Robotic-assisted surgery is moving into a different phase of growth. New competitors with new ideas are coming into the industry and user awareness has been enhanced. UK scale-up CMR Surgical views these as healthy developments, says business development chief Bertrand Weil.

AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins

Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead. 

Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market

Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel